Quisinostat

Quisinostat
Clinical data
Other names	JNJ-26481585
ATC code	None;
Identifiers
	IUPAC name N-Hydroxy-2-[4-({[(1-methyl-1H-indol-3-yl)methyl]amino}methyl)-1-piperidinyl]-5-pyrimidinecarboxamide;
PubChem CID	11538455;
ChemSpider	9713236;
CompTox Dashboard (EPA)	DTXSID90236376 ;
Chemical and physical data
Formula	C21H26N6O2
Molar mass	394.470 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(NO)c1cnc(nc1)N2CCC(CC2)CNCc4c3ccccc3n(c4)C;
	InChI InChI=1S/C21H26N6O2/c1-26-14-17(18-4-2-3-5-19(18)26)11-22-10-15-6-8-27(9-7-15)21-23-12-16(13-24-21)20(28)25-29/h2-5,12-15,22,29H,6-11H2,1H3,(H,25,28); Key:PAWIYAYFNXQGAP-UHFFFAOYSA-N;

Quisinostat (USAN;^[1] development code JNJ-26481585) is an experimental drug candidate for the treatment of cancer. It is a "second generation" histone deacetylase inhibitor with antineoplastic activity.^[2]^[3]^[4]

References

^ "Quisinostat" (PDF). American Medical Association.
^ Tong, Wei-Gang; Wei, Yue; Stevenson, William; Kuang, Shao-Qing; Fang, Zhihong; Zhang, Ming; Arts, Janine; Garcia-Manero, Guillermo (2010). "Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor". Leukemia Research. 34 (2): 221–8. doi:10.1016/j.leukres.2009.07.024. PMID 19682743.
^ Stühmer, Thorsten; Arts, Janine; Chatterjee, Manik; Borawski, Johanna; Wolff, André; King, Peter; Einsele, Hermann; Leo, Eugen; Bargou, Ralf C. (2010). "Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585". British Journal of Haematology. 149 (4): 529–36. doi:10.1111/j.1365-2141.2010.08126.x. PMID 20331455. {{cite journal}}: Unknown parameter |displayauthors= ignored (|display-authors= suggested) (help)
^ "Quisinostat". NCI Drug Dictionary. National Cancer Institute.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.